Dapagliflozin:'Helpful Strategy' for T1D? Dapagliflozin:'Helpful Strategy' for T1D?
Research presented at EASD 2017 shows that dapagliflozin may reduce insulin requirements with a low risk of adverse effects in patients with type 1 diabetes.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 20, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news
Type 2 Diabetes Drug Improves Glycemic Control in Type 1 Diabetes (FREE)
By Amy Orciari Herman
Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS
The type 2 diabetes drug dapagliflozin helps improve glycemic control when added to insulin therapy in patients with type 1 diabetes, according to an … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 14, 2017 Category: Primary Care Source Type: news
Another SGLT2 Drug Shines as Insulin Adjunct in T1D (CME/CE)
(MedPage Today) -- Dapagliflozin lowered HbA1c in phase III trial (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 14, 2017 Category: Cardiology Source Type: news
DEPICT-1: Dapagliflozin Works in T1D With Little Ketoacidosis DEPICT-1: Dapagliflozin Works in T1D With Little Ketoacidosis
Dapagliflozin provided significant reductions in HbA1c, total daily insulin dose, and body weight in type 1 diabetes and was well tolerated, with no new safety signals, in a 24-week trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 14, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients
(University at Buffalo) A majority of patients with type 1 diabetes who were treated with dapagliflozin, a type 2 diabetes medicine, had a significant decline in their blood sugar levels, according to a new study published in The Lancet Diabetes and Endocrinology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 14, 2017 Category: International Medicine & Public Health Source Type: news
dapagliflozin, Farxiga
Title: dapagliflozin, FarxigaCategory: MedicationsCreated: 12/1/2014 12:00:00 AMLast Editorial Review: 8/8/2017 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - August 8, 2017 Category: Endocrinology Source Type: news
Qtern (dapagliflozin and saxagliptin) for the Treatment of Type 2 Diabetes
Qtern (dapagliflozin and saxagliptin) is a combination drug with sodium/glucose cotransporter (SGLT) 2 and dipeptidyl peptidase 4 (DPP-4) inhibitors indicated for the treatment of type 2 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - March 9, 2017 Category: Pharmaceuticals Source Type: news
Qtern (Dapagliflozin and Saxagliptin Tablets, for Oral Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 8, 2017 Category: Drugs & Pharmacology Source Type: news
Qtern (Dapagliflozin and Saxagliptin Tablets, for Oral Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 8, 2017 Category: Drugs & Pharmacology Source Type: news
FDA Finally OKs Dapagliflozin/Saxagliptin for Type 2 Diabetes FDA Finally OKs Dapagliflozin/Saxagliptin for Type 2 Diabetes
After first rejecting it at the end of 2015, the FDA has now approved the AstraZeneca DPP-4 inhibitor/SGLT2 inhibitor fixed-dose combination product Qtern for type 2 diabetes in adults.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 28, 2017 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
FDA approves once-daily Qtern (dapagliflozin and saxagliptin) tablets for adults with type-2 diabetes
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes. The new medicine is indicated as an adjunct to diet and exercise to improve glycaemic (blood sugar level) control in adults with type-2 diabetes who have inadequate control with dapagliflozin (10mg) or who are already treated with dapagliflozin and saxagliptin. (Source: World Pharma News)
Source: World Pharma News - February 28, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
FDA Approves Once-Daily Qtern (dapagliflozin and saxagliptin) Tablets for Adults with Type-2 Diabetes
28 February 2017 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes. The new medicine is indicated as an adjunct... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 28, 2017 Category: Drugs & Pharmacology Source Type: news
Monthly News Roundup - February 2017
FDA Approves Once-Daily Qtern Tablets for Adults with Type 2 Diabetes
The U.S. Food and Drug Administration (FDA) has cleared AstraZeneca’s Qtern (dapagliflozin and saxagliptin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 28, 2017 Category: Pharmaceuticals Source Type: news
AstraZeneca announces availability of saxa / dapa FDC in UK
UK-based AstraZeneca has announced the availability of Qtern (saxagliptin and dapagliflozin fixed-dose combination) for adult patients with type 2 diabetes. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 27, 2017 Category: Pharmaceuticals Source Type: news
NICE recommends dapagliflozin for T2DM triple therapy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 30, 2016 Category: Drugs & Pharmacology Source Type: news
